title: Rapid recurrence of Helicobacter pylori infection in Peruvian patients after successful eradication. Gastrointestinal Physiology Working Group of the Universidad Peruana Cayetano Heredia and The Johns Hopkins University.
abstract: Helicobacter pylori is associated with gastritis, peptic ulcer disease, and gastric cancer. Since gastric cancer is common in Peru, eradication of H. pylori may help to reduce the occurrence of gastric cancer. This study involved three randomized trials to determine the efficacy of four different triple-drug therapy regimens. The most successful regimen was furazolidone combined with bismuth subsalicylate and amoxicillin, which eradicated infection in 82% of patients. Patients successfully treated were followed every 2-3 months to determine the recurrence rate of H. pylori infection. Of 105 patients with H. pylori eradication documented by pathology and culture, 52% (55) returned for follow-up endoscopy, and in 73% (40) of these 55 the infection recurred during the 8-month follow-up period. Thirty-five patients from whom H. pylori was eradicated and who were tested for antibodies to H. pylori remained consistently seropositive. Rapid recurrence of H. pylori infection after successful eradication suggests that measures other than antimicrobial therapy are needed to fight H. pylori in developing countries.
authors.affiliation: Department of Pathology and Medicine of Universidad Peruana Cayetano Heredia, Lima, Peru.
authors.forename: A
authors.initials: A
authors.lastname: Ramirez-Ramos
authors.forename: R H
authors.initials: RH
authors.lastname: Gilman
authors.forename: R
authors.initials: R
authors.lastname: Leon-Barua
authors.forename: S
authors.initials: S
authors.lastname: Recavarren-Arce
authors.forename: J
authors.initials: J
authors.lastname: Watanabe
authors.forename: G
authors.initials: G
authors.lastname: Salazar
authors.forename: W
authors.initials: W
authors.lastname: Checkley
authors.forename: J
authors.initials: J
authors.lastname: McDonald
authors.forename: Y
authors.initials: Y
authors.lastname: Valdez
authors.forename: L
authors.initials: L
authors.lastname: Cordero
authors.forename: J
authors.initials: J
authors.lastname: Carrazco
mesh_terms: D000328:Adult; D000368:Aged; D000658:Amoxicillin / Q000627:therapeutic use; D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D001729:Bismuth / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D005260:Female; D005500:Follow-Up Studies; D005664:Furazolidone / Q000627:therapeutic use; D016481:Helicobacter Infections / Q000188:drug therapy*; D016480:Helicobacter pylori; D006801:Humans; D008297:Male; D008795:Metronidazole / Q000627:therapeutic use; D008875:Middle Aged; D009942:Organometallic Compounds / Q000627:therapeutic use; D010568:Peru; D012008:Recurrence; D012459:Salicylates / Q000627:therapeutic use; D013752:Tetracycline / Q000627:therapeutic use; D014011:Tinidazole / Q000627:therapeutic use
chemical_list: D000900:Anti-Bacterial Agents; D009942:Organometallic Compounds; D012459:Salicylates; D014011:Tinidazole; D008795:Metronidazole; D005664:Furazolidone; C015715:bismuth subsalicylate; D000658:Amoxicillin; D013752:Tetracycline; D001729:Bismuth